MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

Search

Smith & Nephew PLC ADR

Uždarymo kaina

34.04 0.98

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

33.75

Max

34.26

Pagrindiniai rodikliai

By Trading Economics

Pajamos

296M

Pardavimai

3B

P/E

Sektoriaus vid.

30.423

89.037

Dividendų pajamingumas

2.26

Pelno marža

9.895

Darbuotojai

17,000

EBITDA

723M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+3.45% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.26%

2.18%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

15B

Ankstesnė atidarymo kaina

33.06

Ankstesnė uždarymo kaina

34.04

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Smith & Nephew PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-27 23:07; UTC

Uždarbis

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

2026-01-27 21:27; UTC

Uždarbis

Texas Instruments 4Q Sales Rise, Profit Falls

2026-01-27 23:55; UTC

Rinkos pokalbiai

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

2026-01-27 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-27 23:47; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

2026-01-27 23:39; UTC

Rinkos pokalbiai

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

2026-01-27 23:20; UTC

Uždarbis

SK Innovation: Asset-Impairment Losses Weighed on Earnings

2026-01-27 23:20; UTC

Uždarbis

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

2026-01-27 23:19; UTC

Uždarbis

SK Innovation Posts Net Loss for Second Consecutive Year

2026-01-27 23:19; UTC

Uždarbis

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

2026-01-27 23:18; UTC

Uždarbis

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

2026-01-27 23:18; UTC

Uždarbis

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

2026-01-27 23:11; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-27 23:11; UTC

Rinkos pokalbiai

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

2026-01-27 23:07; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

2026-01-27 22:17; UTC

Rinkos pokalbiai

U.S. Dollar Slips Following Trump Comments -- Market Talk

2026-01-27 22:06; UTC

Uždarbis

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

2026-01-27 21:51; UTC

Uždarbis

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

2026-01-27 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-27 21:43; UTC

Uždarbis

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

2026-01-27 21:41; UTC

Uždarbis

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

2026-01-27 21:38; UTC

Uždarbis

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

2026-01-27 21:32; UTC

Uždarbis

Ampol: Modest Profit From F&I International in 2025

2026-01-27 21:32; UTC

Uždarbis

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

2026-01-27 21:31; UTC

Uždarbis

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

2026-01-27 21:31; UTC

Uždarbis

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

2026-01-27 21:30; UTC

Uždarbis

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

2026-01-27 21:29; UTC

Uždarbis

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

2026-01-27 21:29; UTC

Uždarbis

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

2026-01-27 21:28; UTC

Uždarbis

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Akcijų palyginimas

Kainos pokytis

Smith & Nephew PLC ADR Prognozė

Kainos tikslas

By TipRanks

3.45% į viršų

12 mėnesių prognozė

Vidutinis 34.46 USD  3.45%

Aukščiausias 34.91 USD

Žemiausias 34 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Smith & Nephew PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

2 ratings

0

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

26.64 / 28.37Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat